Abstract
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Current Alzheimer Research
Title:Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Volume: 15 Issue: 12
Author(s): Alexandre A. de Castro, Elaine F.F. da Cunha, Ander F. Pereira, Flavia V. Soares, Daniel H.S. Leal, Kamil Kuca and Teodorico C. Ramalho*
Affiliation:
- Department of Chemistry, Federal University of Lavras, Lavras/MG, 37200-000,Brazil
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Abstract: Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Export Options
About this article
Cite this article as:
de Castro A. Alexandre, da Cunha F.F. Elaine , Pereira F. Ander , Soares V. Flavia, Leal H.S. Daniel , Kuca Kamil and Ramalho C. Teodorico *, Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180813150703
DOI https://dx.doi.org/10.2174/1567205015666180813150703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcium Store Stability as an Antiarrhythmic Endpoint
Current Pharmaceutical Design Olanzapine v Risperidone: A Contrast Between Atypical Antipsychotics Concerning Control of Schizophrenia
Current Psychopharmacology Preface- Novel Targets for CNS Anti-Inflammatory Drug Development Interfering with Eicosanoid Formation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Pharmacogenetic Approach for a Better Drug Treatment in Children
Current Pharmaceutical Design Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Structural Characterization of Amyloid β17-42 Dimer by Potential of Mean Force Analysis: Insights from Molecular Dynamics Simulations
Protein & Peptide Letters Beta-propellers: Associated Functions and their Role in Human Diseases
Current Medicinal Chemistry Quantum Molecular Dynamics, Topological, Group Theoretical and Graph Theoretical Studies of Protein-Protein Interactions
Current Topics in Medicinal Chemistry A New Regulatory Road-Map for Alzheimer’s Disease Drug Development
Current Alzheimer Research Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?
Current Medicinal Chemistry - Central Nervous System Agents FDG-PET Scanning Shows Distributed Changes in Cortical Activity Associated with Visual Hallucinations in Eye Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Current Neuropharmacology EDITORIAL: Synthesis and CNS Activity of Medicinal Important Heterocyclic Compounds
Central Nervous System Agents in Medicinal Chemistry Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene
Current Genomics The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry Highly Effective Synthesis of 1-thioamidoalkyl-2-naphthols and Tetrahydropyridines Using a Nanostructured Silica-based Catalyst Under Mild Conditions
Combinatorial Chemistry & High Throughput Screening A Sleeping rs-fMRI Study of Preschool Children with Autism Spectrum Disorders
Current Medical Imaging